What tinnitus actually is

Tinnitus is the perception of sound, most often a ringing, buzzing, or hissing tone, in the absence of an external source. The American Tinnitus Association estimates that roughly 50 million U.S. adults experience some form of it, and around 20 million live with chronic, burdensome tinnitus. For about 2 million people, it is severe enough to interfere with daily functioning, sleep, and concentration.

For a long time, tinnitus was thought of as primarily an ear problem. The current model is more interesting and, frankly, harder to treat. Most chronic tinnitus is generated centrally, in the auditory cortex and adjacent regions of the brain, in response to reduced or distorted input from the cochlea. When the ear stops sending a complete signal, the brain compensates by turning up its own gain, and that elevated activity can be perceived as sound.

This central mechanism is part of why so many tinnitus treatments fail. You cannot mute a phantom by treating the speaker. You have to address the listener. That observation is what made researchers start looking at glutamate, NMDA receptors, and ketamine in the first place.

The glutamate hypothesis and why ketamine got attention

Glutamate is the brain's main excitatory neurotransmitter. NMDA receptors are one of its primary docking sites, and they play a central role in synaptic plasticity, the process by which the brain rewires itself in response to experience. In animal models of acoustic trauma, exposure to loud noise damages cochlear hair cells and triggers a burst of glutamate release in the auditory pathway. That excess glutamate appears to overactivate NMDA receptors and contribute to a kind of maladaptive neural rewiring that researchers consider the cellular substrate of tinnitus.

Once you say the words "NMDA receptors" and "maladaptive plasticity," you are in ketamine's neighborhood. Ketamine is the most clinically familiar NMDA-receptor antagonist in medicine. It is used as an anesthetic, and at lower doses it has substantial evidence in treatment-resistant depression and anxiety through its effects on glutamatergic signaling and neuroplasticity.

So the logic is reasonable on paper. If tinnitus is a glutamatergic plasticity disorder, and ketamine modulates exactly that system, perhaps ketamine can quiet tinnitus. The trouble is that "reasonable on paper" is where many promising therapies have died, and tinnitus pharmacology is one of those graveyards.

What animal trials showed

The foundational paper here is Guitton and colleagues, published in the Journal of Neuroscience in 2003. They demonstrated in rodents that NMDA-receptor-mediated cochlear excitotoxicity could generate tinnitus-like behavior after salicylate exposure or acoustic trauma, and that delivering NMDA antagonists into the cochlea reduced those tinnitus signs. That study, and others that followed, established the rationale for treating tinnitus as an NMDA-driven disorder and motivated a series of human trials.

Animal data has continued to look encouraging in narrow contexts. In rodent models, NMDA antagonists, including ketamine and ketamine-related compounds, can attenuate behavioral signs of tinnitus when given soon after acoustic trauma. The mechanism is plausible, the effect sizes in animals can be meaningful, and the pharmacology is well understood.

The challenge with translating any of this to a human clinic is twofold. First, animals cannot tell you whether a sound has gotten quieter; researchers infer tinnitus from behavior. Second, human chronic tinnitus is rarely the acute, post-acoustic-trauma kind that responds best in animals. By the time a person seeks treatment, the maladaptive changes have usually been in place for months or years.

What human trials of NMDA antagonists actually show

This is where the story breaks down. Multiple human randomized trials have tested NMDA-antagonist drugs as treatments for established tinnitus, including intratympanic and oral compounds developed specifically for the indication. None has produced a clinically meaningful, replicable benefit on primary tinnitus outcomes when compared to placebo.

The most useful synthesis is a 2018 systematic review by Trevis and colleagues that examined the broader landscape of pharmacological and other interventions for tinnitus. The authors concluded that no NMDA-antagonist drug had demonstrated clinically meaningful, replicable benefit over placebo on primary tinnitus outcomes in humans. Several drug-development programs aimed specifically at the NMDA receptor for tinnitus have since wound down for the same reason.

A handful of small case series and uncontrolled reports have described patients who reported subjective tinnitus improvement after intravenous ketamine for other indications, usually depression. We take those reports seriously, because they are real patient experiences, but they are not evidence that ketamine treats tinnitus. They are evidence that some people, some of the time, notice changes in their tinnitus during a period when other things in their nervous system are changing too.

The European Multidisciplinary Tinnitus Guideline, published by Cima and colleagues in 2019, reflects this reality. It identifies cognitive behavioral therapy and tinnitus retraining therapy as the strongest-evidenced interventions, with hearing-aid amplification when hearing loss is present and sound therapy as adjuncts. Pharmacological treatment is not first-line for tinnitus itself outside of clearly comorbid depression or anxiety.

Available human evidence does not support NMDA antagonists, including ketamine, as a primary treatment for chronic tinnitus. The animal rationale has not survived the translation to controlled human trials. — Synthesis of Trevis et al., 2018; Cima et al., European Multidisciplinary Tinnitus Guideline, 2019

Ketamine is FDA-approved as an anesthetic. Its use for any psychiatric or pain condition is off-label, and its use for tinnitus specifically is not supported by current evidence. We will not tell you otherwise.

What we do treat: depression, anxiety, and sleep disruption around tinnitus

Here is where the conversation actually becomes useful, because tinnitus is rarely just a sound problem. It is also a sleep problem, an attention problem, and very often a mood problem. Studies consistently report higher rates of depression, anxiety disorders, and insomnia in people with chronic tinnitus than in matched populations without it. The ringing wears people down. It interrupts sleep, and disrupted sleep amplifies almost every other psychiatric symptom.

Tinnitus-driven depression is not a different illness from depression in general. It responds to the same treatments. Tinnitus-driven anxiety is not a different illness from anxiety in general. Same point. And IV ketamine has substantial evidence for treatment-resistant depression and growing evidence for anxiety symptoms through its effects on glutamatergic signaling and synaptic plasticity.

So when a patient comes to us with tinnitus and a depression that has not responded to standard care, we can have an honest conversation. We are not going to claim we will quiet the ringing. We may be able to help with the depression that the ringing has dragged into your life. Sometimes patients tell us, after a series of infusions, that the tinnitus feels less intrusive even when its loudness has not changed. We treat that as a reasonable secondary outcome of better mood and better sleep, not as evidence that ketamine treated the tinnitus.

Sleep is a related angle. Tinnitus is a major driver of insomnia, and untreated insomnia worsens depression, anxiety, and the perceived intrusiveness of tinnitus itself. Our notes on ketamine and sleep and on ketamine for sleep disorders describe what the evidence does and does not support. The short version: ketamine is not a sleep drug, but improvements in mood and anxiety often translate into better sleep, and better sleep often translates into a quieter relationship with tinnitus.

Realistic outcomes — what a tinnitus patient should expect

If you come to Music City Ketamine with tinnitus as part of your story, our first question is what else is going on. Is there active depression? Anxiety? An insomnia pattern that started or worsened with the tinnitus? Have you seen an ENT or audiologist? Is there hearing loss that has not been addressed?

If the answer is that tinnitus is the only complaint, in isolation, we are likely to redirect you. The right starting place is an audiologist, an ENT, and a clinician versed in CBT for tinnitus. We will tell you that, and we will not book you for an infusion to chase a benefit the evidence does not support. Honesty about what we cannot do is part of the work, and our broader piece on common ketamine myths goes further on the kinds of claims you should be skeptical of.

If the answer is that tinnitus is part of a larger picture that includes depression or anxiety that has not responded to standard care, we can talk about whether ketamine fits the mood condition. Marla Peterson, CRNA, oversees every infusion with anesthesia-level monitoring, including continuous pulse oximetry, blood pressure, and heart-rate tracking. We screen for tinnitus history at intake, we ask you to track tinnitus loudness and intrusiveness between sessions, and we adjust if anything moves in the wrong direction.

What patients sometimes report after a series of infusions for depression: better mood, better sleep, less catastrophizing about the tinnitus, and a sense that the sound has receded into the background even when its measurable loudness has not changed. That is a meaningful improvement in quality of life. It is not, however, the same thing as treating the tinnitus, and we are careful to keep that distinction clear.

When ketamine isn't the right answer (and what is)

For tinnitus itself, the better-evidenced options are not in our clinic. They include:

If a clinic, ours included, ever tells you that a non-evidence-based treatment is the answer to your tinnitus, the right move is to ask for the studies. For ketamine specifically, the honest answer is that the human evidence is not there, and pretending otherwise is not in your interest.

We will say what we can do. We can sit with you, work through whether tinnitus has pulled depression or anxiety into your life, and have a careful conversation about whether ketamine fits the mood picture. We will not invoice you $475 a session for a benefit the literature does not support. Cost transparency is part of how we work, and so is being clear that ketamine for tinnitus itself is not a service we offer.